Literature DB >> 32185093

Proof of concept for stereotactic body radiation therapy in the treatment of functional neuroendocrine neoplasms.

Sten Myrehaug1, Julie Hallet2, William Chu1, Elaine Yong3, Calvin Law2, Angela Assal4, Olexandra Koshkina4, Alexander V Louie1, Simron Singh5.   

Abstract

Dysregulated hormonal production remains a challenge in the management of neuroendocrine neoplasms (NEN). We report 4 cases of patients with functional NEN treated with stereotactic body radiation therapy (SBRT) to either the primary/dominant metastatic site of disease or the end organ of hormonal release. No significant toxicities were observed during or after treatment. Each patient has had biochemical, clinical and radiographic response to therapy, providing proof of concept that SBRT is an effective therapeutic strategy for functional neuroendocrine neoplasms.
© 2020 Old City Publishing, Inc.

Entities:  

Keywords:  Stereotactic radiation; functional; glucagonoma; insulinoma; neuroendocrine

Year:  2020        PMID: 32185093      PMCID: PMC7065890     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  9 in total

1.  Image-guided robotic radiosurgery (CyberKnife) for pancreatic insulinoma: is laparoscopy becoming old?

Authors:  Cristiano Germano Sigismondo Huscher; Andrea Mingoli; Giovanna Sgarzini; Andrea Mereu; Maurizio Gasperi
Journal:  Surg Innov       Date:  2011-12-30       Impact factor: 2.058

Review 2.  GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.

Authors:  Thierry de Baere; Frederic Deschamps; Lambros Tselikas; Michel Ducreux; David Planchard; Ernesto Pearson; Amandine Berdelou; Sophie Leboulleux; Dominique Elias; Eric Baudin
Journal:  Eur J Endocrinol       Date:  2014-11-10       Impact factor: 6.664

3.  Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.

Authors:  David L Chan; Matthew Dixon; Calvin H L Law; Serge Koujanian; Kaitlyn A Beyfuss; Simron Singh; Sten Myrehaug; Julie Hallet
Journal:  Ann Surg Oncol       Date:  2018-03-20       Impact factor: 5.344

4.  Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.

Authors:  William Makis; Karey McCann; Terence A Riauka; Alexander J B McEwan
Journal:  Clin Nucl Med       Date:  2015-11       Impact factor: 7.794

Review 5.  Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Authors:  Simona Grozinsky-Glasberg; Ilan Shimon; Márta Korbonits; Ashley B Grossman
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

6.  Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.

Authors:  Valérie Bernard; Catherine Lombard-Bohas; Marie-Caroline Taquet; François-Xavier Caroli-Bosc; Philippe Ruszniewski; Patricia Niccoli; Rosine Guimbaud; Cécile N Chougnet; Bernard Goichot; Vincent Rohmer; Françoise Borson-Chazot; Eric Baudin
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

7.  External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review.

Authors:  D L Chan; R Thompson; M Lam; N Pavlakis; J Hallet; C Law; S Singh; S Myrehaug
Journal:  Clin Oncol (R Coll Radiol)       Date:  2018-03-31       Impact factor: 4.126

8.  Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy.

Authors:  Kamran A Ahmed; Jimmy J Caudell; Ghassan El-Haddad; Anders E Berglund; Eric A Welsh; Binglin Yue; Sarah E Hoffe; Arash O Naghavi; Yazan A Abuodeh; Jessica M Frakes; Steven A Eschrich; Javier F Torres-Roca
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-08       Impact factor: 7.038

Review 9.  Gastroenteropancreatic neuroendocrine tumours.

Authors:  Irvin M Modlin; Kjell Oberg; Daniel C Chung; Robert T Jensen; Wouter W de Herder; Rajesh V Thakker; Martyn Caplin; Gianfranco Delle Fave; Greg A Kaltsas; Eric P Krenning; Steven F Moss; Ola Nilsson; Guido Rindi; Ramon Salazar; Philippe Ruszniewski; Anders Sundin
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.